Tag: oral dissolving

Canntab Therapeutics (PILL.C) announced today that it has reached an agreement with 36Eight Technologies (“36Eight”), whereby “36Eight” will list, market, and support all of Canntab’s market-exclusive and patent-protected solid and exact dose products. “This is an exciting opportunity for Canntab, as we believe 36Eight’s unique and valuable complementary platform will support our ability to provide…